Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma
Public ClinicalTrials.gov record NCT03410693. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy
Study identification
- NCT ID
- NCT03410693
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 175 participants
Conditions and interventions
Conditions
Interventions
- Chemotherapy Drug
- Rogaratinib (BAY1163877) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2018
- Primary completion
- Oct 26, 2020
- Completion
- Oct 26, 2020
- Last update posted
- Sep 27, 2022
2018 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Clinical Research Center, LLC | Anchorage | Alaska | 99503 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Centers | Littleton | Colorado | 80120-4413 | — |
| UF Cancer Center at Orlando Health | Orlando | Florida | 32806 | — |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Compass Oncology | Tigard | Oregon | 97223 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | — |
| Bon Secours St. Francis Hospital | Greenville | South Carolina | 29607 | — |
| Texas Oncology-Denton South | Denton | Texas | 76210 | — |
| Houston Methodist Hospital | Houston | Texas | 77030-2707 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Summit Cancer Center | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 145 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03410693, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2022 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03410693 live on ClinicalTrials.gov.